<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-21T01:13:19Z</responseDate><request verb="GetRecord" identifier="oai:macsphere.mcmaster.ca:11375/13367" metadataPrefix="dim">https://prod-ms-be.lib.mcmaster.ca/server/oai/request</request><GetRecord><record><header><identifier>oai:macsphere.mcmaster.ca:11375/13367</identifier><datestamp>2026-09-24T00:12:30Z</datestamp><setSpec>com_11375_271</setSpec><setSpec>col_11375_272</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor" lang="en_US">Sheffield, William P.</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="advisor" lang="en_US">Junop, Murray</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="advisor" lang="en_US">Bramson, Jonathan</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author" lang="en_US">Scott, Benjamin M.</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="department" lang="en_US">Medical Sciences (Thrombosis &amp; Haemostasis &amp; Atherosclerosis)</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2014-06-18T17:03:45Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2014-06-18T17:03:45Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="created" lang="en_US">2013-08-23</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued" lang="en_US">2013-10</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other" lang="en_US">opendissertations/8189</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other" lang="en_US">9130</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other" lang="en_US">4492736</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/11375/13367</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://doi.org/10.71548/15282</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">&lt;p>α&lt;sub>1&lt;/sub>-proteinase inhibitor (α&lt;sub>1&lt;/sub>-PI) is the most abundant serine protease inhibitor (serpin) in plasma. The α&lt;sub>1&lt;/sub>-PI M358R mutant exhibits greatly increased rates of thrombin inhibition compared to wild type α&lt;sub>1&lt;/sub>-PI, which predominantly inhibits neutrophil elastase. M358R (P1) lies at the reactive centre (P1-P1’) bond of the reactive centre loop (RCL) of α&lt;sub>1&lt;/sub>-PI, cleaved by cognate proteases as they become trapped in the serpin-type inhibitory complex. The relationship between RCL structure and serpin inhibitor function is incompletely understood and has not been subjected to saturation mutagenesis. α&lt;sub>1&lt;/sub>-PI M358R is a less potent inhibitor of thrombin than natural thrombin-inhibitory serpins, suggesting room for engineered improvement into an antithrombotic protein drug.&lt;/p> &lt;p>Phage display is a powerful tool for screening mutant protein libraries, but only one serpin (PAI-1) has previously been mutated and expressed in this manner. In this study the T7Select10-3b (Novagen) phage display system was used to express α&lt;sub>1&lt;/sub>-PI variants and PAI-1, fused to the first 348 residues of the T7 10B coat protein. Following confirmation that α&lt;sub>1&lt;/sub>-PI M358R retained inhibitory activity when fused to T7Select10-3b phage, this system was used to express a library of α&lt;sub>1&lt;/sub>-PI mutant proteins with all possible codon combinations at positions P2 (P357) and P1 (M358) (441 mutants). The library was biopanned using a novel technique in order to amplify only the α&lt;sub>1&lt;/sub>-PI P2P1 mutants capable of forming stable complexes with thrombin. The P357/M358R mutant was the only P2P1 mutant enriched, indicating that the α&lt;sub>1&lt;/sub>-PI M358R protein has the optimal P2P1 sequence for thrombin inhibition.&lt;/p> &lt;p>A second T7Select10-3b library of α&lt;sub>1&lt;/sub>-PI mutant proteins was generated to identify the optimal sequence at positions P7 through to P3 (amino acids 352-356) for thrombin inhibition. The P2 and P1 positions were maintained at P357/M358R, while all possible codon combinations at positions P7 through to P3 were represented (>4.08 million mutants). The library was biopanned using the protocol developed for the P2P1 library, before sequences were inserted into an &lt;em>E. coli&lt;/em> expression vector and α&lt;sub>1&lt;/sub>-PI M358R P7-P3 mutants were screened for thrombin inhibitory activity. 80 individual colonies were screened, yielding 22 unique P7-P3 mutants with thrombin inhibitory activity greater than the M358R RCL sequence. The consensus observed in sequences with improved activity matched thrombin’s known substrate specificity and also general RCL trends: P7-Not Aromatic/P6-Hydrophobic/P5-T or S/P4-Hydrophobic/P3-Not Aromatic.&lt;/p> &lt;p>Kinetic characterization of selected mutants with improved thrombin inhibitory activity yielded two mutants, P7-P3 sequence DITMA and AAFVS, with a second order rate constant of 1.0 x 10&lt;sup>6&lt;/sup> M&lt;sup>-1&lt;/sup>s&lt;sup>-1&lt;/sup>. This represents a >2-fold increase in the rate of thrombin inhibition versus α&lt;sub>1&lt;/sub>-PI M358R. Both the DITMA and AAFVS mutants were found to have a lower stoichiometry of inhibition compared to α&lt;sub>1&lt;/sub>-PI M358R, indicating that an improved thrombin inhibitory mechanism was also enriched during biopanning.&lt;/p> &lt;p>These findings suggest that based on the scaffold of the α&lt;sub>1&lt;/sub>-PI protein, improved thrombin inhibitory activity can be engineered and selected via phage display. Additionally, this work represents a proof-of-principle for the application of this system to screen libraries of up to 10 million mutants in order to better engineer serpins towards a desired activity.&lt;/p></dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degree" lang="en_US">Master of Health Sciences (MSc)</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">protein engineering</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">thrombin</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">phage display</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">coagulation</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">serpin</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">thrombin inhibitor</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Amino Acids, Peptides, and Proteins</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Amino Acids, Peptides, and Proteins</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">Applying Phage Display to Screen a Library of α1-Proteinase Inhibitor Mutants for Improved Thrombin Binding Activity</dim:field>
   <dim:field mdschema="dc" element="type" lang="en_US">thesis</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim></metadata></record></GetRecord></OAI-PMH>